异环磷酰胺和顺铂化疗用于转移性或复发性宫颈癌的II期研究。
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
作者信息
Coleman R E, Clarke J M, Slevin M L, Sweetenham J, Williams C J, Blake P, Calman F, Wiltshaw E, Harper P G
机构信息
Guy's Hospital, London, UK.
出版信息
Cancer Chemother Pharmacol. 1990;27(1):52-4. doi: 10.1007/BF00689276.
A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic deaths. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.
共有44名女性接受了异环磷酰胺（每日1.5 g/m²，共5天）和顺铂（仅在第1天使用50 mg/m²）联合治疗，作为复发性或转移性宫颈癌的一线化疗方案。总共有12/42（38%）可评估患者出现缓解，缓解的中位持续时间为7个月。骨髓和胃肠道毒性常常很严重。有3例因感染死亡。虽然顺铂加异环磷酰胺是针对该疾病的一种有效的联合方案，但这些结果表明，其疗效并不比单独使用任何一种药物更好。
Zotero 插件